148 related articles for article (PubMed ID: 10786197)
1. [Topotecan: a new field of use].
Ferrari S; Danova M
Tumori; 1999; 85(6 Suppl 1):S23-8. PubMed ID: 10786197
[TBL] [Abstract][Full Text] [Related]
2. Topotecan - A novel topoisomerase I inhibitor: pharmacology and clinical experience.
Kollmannsberger C; Mross K; Jakob A; Kanz L; Bokemeyer C
Oncology; 1999; 56(1):1-12. PubMed ID: 9885371
[TBL] [Abstract][Full Text] [Related]
3. [Preclinical pharmacology and clinical uses of topotecan].
Del Tacca M; Di Paolo A; Danesi R
Tumori; 1999; 85(6 Suppl 1):S3-11. PubMed ID: 10786194
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of topotecan in the treatment of advanced ovarian carcinoma.
ten Bokkel Huinink W; Carmichael J; Armstrong D; Gordon A; Malfetano J
Semin Oncol; 1997 Feb; 24(1 Suppl 5):S5-19-S5-25. PubMed ID: 9122738
[TBL] [Abstract][Full Text] [Related]
5. Review of phase I clinical studies with topotecan.
Rowinsky EK; Verweij J
Semin Oncol; 1997 Dec; 24(6 Suppl 20):S20-3-S20-10. PubMed ID: 9425956
[TBL] [Abstract][Full Text] [Related]
6. Induction of apoptosis by topotecan: implications for the treatment of leukemia.
Seiter K
Semin Hematol; 1998 Jul; 35(3 Suppl 4):22-5. PubMed ID: 9779878
[TBL] [Abstract][Full Text] [Related]
7. [Topotecan: prospects for using it in combination therapy for ovarian carcinoma].
Scarfone G
Tumori; 1999; 85(6 Suppl 1):S12-5. PubMed ID: 10786195
[TBL] [Abstract][Full Text] [Related]
8. Topotecan in the treatment of hematologic malignancies.
Beran M; Kantarjian H
Semin Hematol; 1998 Jul; 35(3 Suppl 4):26-31. PubMed ID: 9779879
[TBL] [Abstract][Full Text] [Related]
9. Preliminary results of combined therapy with topotecan and carboplatin in advanced non-small-cell lung cancer.
Pujol JL; von Pawel J; Tumolo S; Martoni A; Hearn S; Fields SZ; Ross G
Oncology; 2001; 61 Suppl 1():47-54. PubMed ID: 11598415
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of topotecan in resistant and relapsing multiple myeloma: a Southwest Oncology Group study.
Kraut EH; Crowley JJ; Wade JL; Laufman LR; Alsina M; Taylor SA; Salmon SE
J Clin Oncol; 1998 Feb; 16(2):589-92. PubMed ID: 9469346
[TBL] [Abstract][Full Text] [Related]
11. Topoisomerase I inhibition with topotecan: pharmacologic and clinical issues.
Arun B; Frenkel EP
Expert Opin Pharmacother; 2001 Mar; 2(3):491-505. PubMed ID: 11336601
[TBL] [Abstract][Full Text] [Related]
12. Update on the role of topotecan in the treatment of non-small cell lung cancer.
Stewart DJ
Oncologist; 2004; 9 Suppl 6():43-52. PubMed ID: 15616149
[TBL] [Abstract][Full Text] [Related]
13. A phase I and translational study of sequential administration of the topoisomerase I and II inhibitors topotecan and etoposide.
Hammond LA; Eckardt JR; Ganapathi R; Burris HA; Rodriguez GA; Eckhardt SG; Rothenberg ML; Weiss GR; Kuhn JG; Hodges S; Von Hoff DD; Rowinsky EK
Clin Cancer Res; 1998 Jun; 4(6):1459-67. PubMed ID: 9626463
[TBL] [Abstract][Full Text] [Related]
14. A phase I and pharmacological study of topotecan infused over 30 minutes for five days in patients with refractory acute leukemia.
Rowinsky EK; Kaufmann SH; Baker SD; Miller CB; Sartorius SE; Bowling MK; Chen TL; Donehower RC; Gore SD
Clin Cancer Res; 1996 Dec; 2(12):1921-30. PubMed ID: 9816150
[TBL] [Abstract][Full Text] [Related]
15. Topotecan dosing guidelines in ovarian cancer: reduction and management of hematologic toxicity.
Armstrong DK
Oncologist; 2004; 9(1):33-42. PubMed ID: 14755013
[TBL] [Abstract][Full Text] [Related]
16. A phase II study of topotecan in non-Hodgkin's lymphoma: an Ohio State University phase II research consortium study.
Kraut EH; Balcerzak SP; Young D; Davis MP; Jacobs SA;
Cancer Invest; 2002; 20(2):174-9. PubMed ID: 11901536
[TBL] [Abstract][Full Text] [Related]
17. Topotecan in squamous cell carcinoma of the cervix: A Phase II study of the Gynecologic Oncology Group.
Bookman MA; Blessing JA; Hanjani P; Herzog TJ; Andersen WA
Gynecol Oncol; 2000 Jun; 77(3):446-9. PubMed ID: 10831357
[TBL] [Abstract][Full Text] [Related]
18. Topotecan in the treatment of gynecologic cancer.
Coleman RL; Miller DS
Semin Oncol; 1997 Dec; 24(6 Suppl 20):S20-55-S20-63. PubMed ID: 9425962
[TBL] [Abstract][Full Text] [Related]
19. Schedule-dependent activity of topotecan in OVCAR-3 ovarian carcinoma xenograft: pharmacokinetic and pharmacodynamic evaluation.
Guichard S; Montazeri A; Chatelut E; Hennebelle I; Bugat R; Canal P
Clin Cancer Res; 2001 Oct; 7(10):3222-8. PubMed ID: 11595718
[TBL] [Abstract][Full Text] [Related]
20. A dose-escalating study of weekly bolus topotecan in previously treated ovarian cancer patients.
Homesley HD; Hall DJ; Martin DA; Lewandowski GS; Vaccarello L; Nahhas WA; Suggs CL; Penley RG
Gynecol Oncol; 2001 Nov; 83(2):394-9. PubMed ID: 11606103
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
